Peptide

(NT-proBNP) in Children with Chronic Kidney

M. Okarska-Napierala¹, H. Ziolkowska¹, R. Pietrzak², P. Skrzypczyk¹, K. Jankowska¹, B. Werner², M. Roszkowska-Blaim¹

¹Department of Pediatrics and Nephrology, Medical University of Warsaw, Warsaw, POLAND



INTRODUCTION

Cardiovascular disease (CVD) is a frequent complication of chronic kidney disease (CKD) and a leading cause of increased mortality in young adults with CKD. One of biochemical markers of myocardial damage and stress is NT-proBNP. Its correlation with cardiac strain was proved in both adults and children with CKD.

The aim of this study was to determine relations between serum levels of NTproBNP, calcium-phosphorus metabolism parameters and echocardiographic results in children with CKD.

METHODS

22 children (10 boys), aged 10.9 ± 5.6 years, with CKD stage 2 - 5, were included in the study. All children attended the CKD management clinic at the Department of Pediatrics and Nephrology of Medical University of Warsaw from 2013 to 2014. Children with congenital or aquired cadriac defects were excluded from the study.

In all children serum concentrations of creatinine, alkaline phosphatase (ALP), 25hydroxyvitamin D₃ (25(OH)D), calcium (Ca), phosphorus (P), parathormone (PTH) and NT-proBNP were measured at one time. NT-proBNP concentration was determined with use of Enzyme-Linked Fluorescent Assay (ELFA) technique. Normal value for NTproBNP was < 125.0 pg/ml. In 18 children transthoracic echocardiography was performed concomitantly. Renal function was determined by eGFR using the new revised Schwartz formula.

The study protocol was approved by the Medical University of Warsaw Ethics Committee.

	CKD 2 (n = 6)	CKD 3-4 (n = 10)	CKD 5 (n = 6)	p value	Overall (n = 22)
NT-proBNP median (lower, upper quartile)	68 (32, 118)	106 (52, 158)	665.5 (317, 1579)	0.01*a	94 (52, 317)
PTH median (lower, upper quartile)	49.25 (15.2, 56.9)	38 (29.6, 62.2)	199.5 (89, 656)	0.01*a	54.45 (35.9, 67.3)
25(OH)D median (lower, upper quartile)	22.05 (21.2, 29.6)	25.4 (16.4, 31.6)	32.85 (22.9, 37.8)	NS	25.4 (21.2, 31.6)
ALP median (lower, upper quartile)	194.5 (172, 204)	160 (96, 230)	269.5 (145, 407)	NS	202 (134, 230)
P mean ± SD	2.8 ± 0.53	2.84 ± 0.43	3.32 ± 0.39	NS	2.96 ± 0.48

^{*} significant at p < 0.05 (Spearman test)

RESULTS

Laboratory results are presented in the table. In group CKD 5 NT-proBNP and PTH levels were significantly increased. Concurrently, the highest levels of left ventricular mass index (LVMI) on echocardiographic examination were observed in this group.


NT-proBNP was found to correlate negatively with glomerular filtration rate (GFR) (R = -0.61, p = 0.002) and positively with PTH (R = 0.49, p = 0.02) and P(R =0.5, p = 0.02).

CONCLUSIONS

- 1) In children with advanced CKD, calcium-phosphate metabolism disturbances may influence development of cardiovascular disease.
- Relationships between cardiac strain markers and other parameters of calcium-phosphate metabolism in children with CKD necessitate further investigation

REFERENCES

- Foley R.N., Parfrey P.S., Sarnak M.J.: Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis. 1998, 32, S112.
- DeFilippi C.R., Fink J.C., Nass C.M., Chen H., Christenson R.: N-terminal pro-B-type natriuretic peptide for predicting coronary disease and left ventricular hypertrophy in asymptomatic CKD not requiring dialysis. Am J Kidney Dis. 2005, 46, 35
- Zoccali C., Mallamaci F., Benedetto F.A., Tripepi G., Perlongo S., Cataliotti A., Cutrupi S., Giacone G., Bellanuova I., Cottini E., Malatino L.S.: Cardiac natriuretic peptides are related to left ventricular mass and function and predict mortality in dialysis patients. J Am Soc Nephrol. 2001, 12, 1508
- Rinat C., Becker-Cohen R., Nir A., Feinstein S., Algur N., Ben-Shalom E., Farber B., Frishberg Y.: B-type natriuretic peptides are reliable markers of cardiac strain in CKD pediatric patients. Pediatr Nephrol. 2012, 27, 617







²Department of Pediatric Cardiology and General Pediatrics, Medical University of Warsaw, Warsaw, POLAND

a between CKD 5 and either CKD 2 or CKD 3-4